Melanopsin-expressing Retinal Ganglion Cells in Control vs. Glaucomatous Retinas by Hamad, Edward
The University of Akron 
IdeaExchange@UAkron 
Williams Honors College, Honors Research 
Projects 
The Dr. Gary B. and Pamela S. Williams Honors 
College 
Spring 2020 
Melanopsin-expressing Retinal Ganglion Cells in Control vs. 
Glaucomatous Retinas 
Edward Hamad 
ejh80@zips.uakron.edu 
Follow this and additional works at: https://ideaexchange.uakron.edu/honors_research_projects 
 Part of the Eye Diseases Commons, Neurosciences Commons, Ophthalmology Commons, and the 
Sense Organs Commons 
Please take a moment to share how this work helps you through this survey. Your feedback will 
be important as we plan further development of our repository. 
Recommended Citation 
Hamad, Edward, "Melanopsin-expressing Retinal Ganglion Cells in Control vs. Glaucomatous 
Retinas" (2020). Williams Honors College, Honors Research Projects. 1113. 
https://ideaexchange.uakron.edu/honors_research_projects/1113 
This Dissertation/Thesis is brought to you for free and open access by The Dr. Gary B. and Pamela 
S. Williams Honors College at IdeaExchange@UAkron, the institutional repository of The University 
of Akron in Akron, Ohio, USA. It has been accepted for inclusion in Williams Honors College, 
Honors Research Projects by an authorized administrator of IdeaExchange@UAkron. For more 
information, please contact mjon@uakron.edu, uapress@uakron.edu. 
  
 
 
 
 
Melanopsin-expressing Retinal Ganglion Cells in Control vs. Glaucomatous Retinas 
Edward (EJ) Hamad 
Sponsor: Dr. Jordan M. Renna 
Readers: Dr. Richard Londraville, Dr. Qin Liu 
Honors Faculty Advisor: Dr. Brian Bagatto 
The University of Akron’s Department of Biology 
The Williams Honors College 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
Glaucoma is a common cause of vision loss worldwide and has a large scope of 
symptoms, ranging from pupillary reflex defects to sleep disorders. These issues can be 
explained partially by a recently found subtype of retinal ganglion cells that express melanopsin, 
denoted melanopsin-expressing retinal ganglion cells or mRGCs for short. These cells function 
primarily as photoreceptors in the non-image forming pathway, but can receive input from rods 
and cones. Since mRGCs play a role in the pupillary reflex and regulation of the sleep-wake 
cycle, I investigated if glaucoma leads to the degeneration of these cells in a mouse model at 4 
months of age. This study focused on a specific type of mRGC, the M1 cell, due to this being 
the most abundant mRGC in the retina. I compared soma size, dendritic path length, and 
dendritic field size to a control and ran a statistical analysis. I found that glaucoma does not 
have an effect on M1 mRGCs at 4 months of age, and further research is needed to track the 
degeneration process.  
 
Introduction 
Glaucoma is a group of progressive optic diseases that leads to the degeneration of 
retinal ganglion cells resulting in visual loss (Weinreb et al. 2014; Mahabadi et al. 2019). It is the 
second most common cause of vision loss and affects up to an estimated 79 million people 
worldwide (Quigley and Broman 2006). The most common pathological signs of glaucoma 
include an increase in intraocular pressure (IOP) and an asymmetric optic disc appearance 
(Weinreb et al. 2014; Mahabadi et al. 2019). The elevated IOP levels caused by the increased 
resistance to the drainage of aqueous humor into the trabecular meshwork can damage the 
axons of retinal ganglion cells that form the optic nerve (Mahabadi et al. 2019). Since retinal 
ganglion cells play a role in both central and peripheral vision, patients affected by glaucoma 
have tunnel vision due to the degeneration of these cells (Khaw 2004). Another symptom that 
glaucomatous patients have shown is a decrease in sleep quality and an increased prevalence 
of sleep disorders (Gracitelli et al. 2016), as well as defects in the pupillary reflex (Skorkovská et 
al. 2011). These issues can be attributed to a specific subtype of retinal ganglion cells classified 
as melanopsin-expressing retinal ganglion cells (mRGCs). These cells are located in the 
ganglion cell layer (GCL) and inner nuclear layer (INL) of the retina and function as non-image 
forming photoreceptors (Obara et al. 2016). They are involved in the pupillary light reflex and 
the suppression of melatonin, which regulates circadian rhythms. It can be concluded that if 
these mRGCs are impaired in a patient, then photoentrainment of circadian rhythms will 
become dysfunctional and the patient will experience sleep disorders, as seen in patients with 
glaucoma.  
 
There are currently six distinct subtypes of melanopsin ganglion cells, classified as 
M1-M6 (Cui et al. 2015; Sondereker et al. 2020). This study looked at M1 cells, whose soma is 
normally located in the GCL, but can be displaced into the INL (Hannibal et al. 2017; 
Sondereker et al. 2020). Thus, there are two subtypes, the displaced (M1d) and the 
conventional (M1) cells. These are outer stratifying cells that project into the inner plexiform 
layer (IPL) and have a higher level of melanopsin expression than the other subtypes, as well as 
having a higher density within the retina (Lax et al. 2019). These cells can be easily visualized 
once stained and imaged, and this will serve as my rationale for selecting this specific subtype.  
 
This study focused on the effect that glaucoma has on M1 mRGCs from birth until 
4-months of age. These cells inside retinal quadrants were examined and factors such as 
density of mRGCs, soma size, dendritic path length, and dendritic field size were recorded and 
analyzed. Current research is ambiguous on whether glaucoma has an effect on mRGCs. Some 
studies state that suppression of melatonin after light exposure in glaucoma patients was 
dysfunctional, and that these findings were consistent with animal models that showed a 
reduction in mRGC density (Obara et al. 2016). However, other studies found that mRGCs are 
spared in glaucomatous animal models even after 3 months of ocular hypertension (Li et al. 
2006), and that mRGCs may be resistant to increased IOP levels at 5 months (Zhang et al. 
2013). I hope that by comparing morphological differences in mRGCs between glaucomatous 
and control retinas, I can contribute to either side of this ongoing debate.  
 
Methods 
DBA/2J mice were ordered from Jackson Laboratory that were genetically predisposed 
to have glaucoma as they aged. DBA/2J-Gpnmb​+​/SjJ mice were used as a control since they 
were a genetic match for the DBA/2J without developing glaucoma. Both mice were raised on a 
12 hour light/12 hour dark schedule. The glaucomatous mice developed for around 4 months 
and the control mice around 5 months when they were euthanized and their retinas were 
dissected. Issues arose with the breeding colonies so a 5-month control had to be used instead 
of a 4-month. Nonetheless, the difference of a month should not affect the integrity of the 
mRGCs in the control. The antibodies that were used can be found in Sondereker et al. 2017, 
as well as the immunohistochemistry protocol for staining the retina. A confocal microscope was 
then used to image cross sections of the retina to form a Z-stack (Sondereker et al. 2017). To 
determine the spatial orientation of the retina, the s-opsin gradient was used (Sondereker et al. 
2018) and the quadrants were labeled accordingly as seen in figure 1. Two quadrants of the 
retina were randomly chosen (nasal and ventral) and melanopsin cells were identified and 
counted within the set boundaries of those quadrants. This can be seen in figure 2. These set 
boundaries were measured out to be 3000x3000 pixels, and each pixel was 3.1 microns. Simple 
Neurite Tracer on ImageJ (Longair et al. 2011) was used to manually trace these neurons and 
measure the size of the somas, dendritic path lengths, and field size of the dendrites. This 
process can be seen in figure 3. Any neuron that had poorly visible dendrites was not traced 
and omitted from the data set. The collected data was further analyzed using Excel and 
subjected to T-Tests to determine if any significant differences existed between the 
glaucomatous and control groups.  
 
 Figure 1. Shows the imaged retina with the quadrants labeled and boundaries set. Using the s-opsin 
gradient, the bottom most quadrant was labeled as the ventral and the top left as nasal.  
 Figure 2. Shows an example of a quadrant with the mRGCs labeled within. All mRGCs within the boundaries were 
traced and their pertinent characteristics measured.  
 Figure 3. The top image is the manual tracing of the M1 mRGC through a Z-stack. The bottom image is the polygon 
feature that was used to mark the outermost points of the dendrite to measure the field size.  
 
 
 
 
Results 
There were no significant differences between the glaucoma and control group for the 
combined quadrants, as seen in figure 4. There were 50 somas total in the nasal (23) and 
ventral (27) quadrants of the 4-month glaucomatous retina and 61 somas total in the nasal (31) 
and ventral (30) quadrants of the 5-month 
control retina. Of these 50 glaucomatous 
somas, 48 had traceable dendrites. 
Meanwhile, out of the 61 control somas, 60 
had traceable dendrites. The glaucomatous 
retina had 6 displaced M1 cells, all in the 
nasal quadrant. The control retina had 2 
displaced M1 cells, split between the ventral 
and nasal quadrants. The average 
glaucomatous soma size was 14.62 µm while 
the average control soma size was 14.33 µm. 
After doing an unpaired T-test assuming 
unequal​ ​variances, the difference between 
the soma sizes was statistically not 
significant (p=0.49). The average  
 
Figure 4. Shows the results for the combined 
quadrants. There were no significant differences 
present. N = 50 glaucoma and 61 control somas.  
N = 48 glaucoma and 60 control dendrites. Error bars 
represent standard error.  
glaucomatous dendritic length was 1270.65 µm while the average control dendritic 
length was 1118.05 µm. After doing an unpaired T-test assuming unequal variances, the 
difference between the dendritic lengths was statistically not significant (p=0.17). The average 
glaucomatous field size was 44584.51 µm while the average control field size was 41245.80 
µm. After doing an unpaired T-test assuming unequal variances, the difference between the 
field sizes was statistically not significant 
(p=0.58). 
       There was a significant difference 
between the size of the glaucomatous and 
control somas in the ventral quadrant, as 
seen in figure 5. No other significant 
differences between the groups existed within 
the ventral quadrant. The ventral quadrants of 
the glaucomatous and control retinas had 23 
somas and 31 somas, respectively. The 
average size of these somas in the 
glaucomatous group was 15.75 µm, while the 
control had an average of 14.35 µm.  
 
Figure 5. Shows the results for the ventral data set. N = 
23 glaucoma and 31 control somas. N = 21 glaucoma 
and 30 control dendrites. Asterisks represent a 
significant difference (p<0.05). Error bars represent 
standard error. 
 
The glaucomatous somas were significantly larger than the control (p=0.02).  
The dendritic lengths in the ventral quadrants were then analyzed. The glaucomatous group had 
an average path length of 1609.59 µm, and the control had an average of 1423.91 µm. These 
results were not significant (p=0.24). The glaucomatous field size of the somas in the ventral 
quadrant had an average of 62061.35 
µm, and the control had an average of 
55499.32 µm. These were not 
significantly different (p=0.48). 
       There were no significant differences 
between the glaucoma and control in the 
nasal quadrant, as seen in figure 6. The 
nasal quadrant of the glaucoma group 
had 27 somas, while the control had 30 
somas. The average size of the somas in 
the glaucomatous was 13.65 µm, and in 
the control the average size was 14.31 
µm. There was not a significant  
 
Figure 6. Shows the results for the nasal data set. 
N = 27 glaucoma and 30 control somas and 
dendrites. There were no significant differences 
present. Error bars represent standard error.  
 
 
difference between the soma sizes in the nasal quadrant (p=0.23). 
In the nasal quadrant, the glaucomatous dendritic lengths were averaged out to be 
1007.04 µm, and the control lengths were calculated to be 812.18 µm. These results were not 
significant (p=0.09). The average field size of the glaucomatous neurons was 30991.42 µm, 
while the control was 26992.27 µm. There was not a significant difference present (p=0.42).  
A regression was done to see if soma size affected the dendritic lengths of the neurons 
in both groups. For the glaucomatous retina, the R​2​ value was 0.119, indicating that there was 
no relationship between the two. For the control retina, the R​2​ value was 0.006, also indicating 
that soma size did not affect the dendritic length. There was a positive regression for both 
groups when comparing the dendritic length and field size (glaucoma R​2​=0.711; control 
R​2​=0.766), indicating that as the dendritic length increased, there was an observed increase in 
the field size. This is seen in figure 7.  
Tables that summarize the data can be viewed in the appendix.  
 
 
 Figure 7. Regression analysis between soma size and dendritic length, dendritic length and field size, and soma size 
and field size in the glaucomatous and control group. Only the dendritic length and field size in both groups showed a 
positive regression. Each regression was highly significant (p<.00001). 
 
 
Discussion 
This study looked at M1 melanopsin expressing retinal ganglion cells and how they are 
affected by glaucoma at 4 months of age in mice. A 5-month old control retina was used as a 
comparison. It is known that the number of mRGCs within the retina in rat models do not 
decrease until 18-24 months of age, so I can conclude that no natural degeneration has 
occurred at 5 months (Lax et al. 2016). Due to time restraints and computing power, two 
quadrants of the retinas were randomly selected and all M1 mRGCs within set boundaries were 
identified and manually traced. Soma size, dendritic length, and field size of the dendrites were 
measured and statistically analyzed. Assuming a p-value less than 0.05 supports a significant 
difference, T-tests were ran to determine if any existed. The sizes of the somas in the 
glaucomatous retina were slightly larger than the control retina, but no significant difference was 
found (p=0.49). Interestingly, when the somas were divided into their respective quadrants, the 
glaucomatous neurons in the ventral quadrant were significantly larger than the control neurons 
(p=0.02). More research needs to be conducted to resolve this issue. 
The lengths of the dendrites in the glaucomatous retina were also larger than the control, 
but no significant difference was found (p=0.17). The field size of the dendrites was found to 
have no significant difference between the two groups (p=0.56). These results were similar even 
when they were broken down into their separate quadrants. Also, increasing the dendritic 
lengths of the neuron led to an observed increase in the field size, which makes sense since 
longer dendrites would cover a larger area. Looking at these results, it can be concluded that 
glaucoma does not have a significant effect on M1 mRGCs at 4 months of age. Based on the 
raw numbers, however, there is a different story. Some studies have concluded that glaucoma 
causes a loss of the other subtypes of mRGCs that this study did not look at, meanwhile M1 
mRGCs would remain intact (Pérez de Sevilla Müller et al. 2014; Lax et al. 2019). Due to the 
loss of other dendrites in the INL, M1 cells may elongate their dendrites to make up for the lost 
synaptic connections (Pérez de Sevilla Müller et al. 2014). Another variable that may explain the 
larger dendritic path length and field size is the cell count. In both glaucomatous quadrants, 
there were less M1 cells present compared to the control group. Where the density of cells is 
decreased, there is an observed increase in dendritic size (Lax et al. 2019). Therefore, if 
glaucoma did not reduce the number of cells present, then the retina was already disposed to 
having less M1 mRGCs and greater field sizes. More research is needed to look at the 
progression of M1 cells in a glaucomatous model in mice before any conclusion can be 
reached.  
There are several factors that still need to be accounted for. The genetic background of 
the mice may play a role in the results, since the number of M1 melanopsin ganglion cells in 
developing retinas may be higher in certain mouse lines (Sondereker et al. 2020). The fact that 
only two quadrants of one mouse for both groups were analyzed may lead to bias in my results. 
A larger sample size is needed to fully verify my findings. A range of ages is needed since 4 
months may not be enough for glaucoma to affect the mRGCs, and to track the progression of 
the degeneration of the retina. There is no way of knowing if the glaucomatous retina had 
already undergone loss of mRGCs. There were 50 neurons counted in the two quadrants of the 
glaucomatous retina compared to the 61 in the control, but it is known that the distribution of 
mRGCs in the retina is not uniformed (Lax et al. 2019). Thus, the quadrants randomly chosen 
could possibly be unrepresentative of the whole retina.  
 
 
 
 
Conclusion 
This study looked at the effects of glaucoma on M1 mRGCs in mice at 4 months of age. I 
examined two quadrants of the retina and ran an analysis on soma size, dendritic length, and 
field size across a glaucomatous retina and a control. There was no significant difference 
present, except for in the ventral retina where glaucomatous mRGCs had a significantly larger 
soma size than the control. Further studies need to be done to find out why this may be the 
case. Looking at the raw data, the glaucomatous retina did have larger dendrites, and several 
hypotheses were given as an explanation. In all, I found that glaucoma does not affect M1 
mRGCs at 4 months of age, and more research is needed to track the progression of the 
degeneration of these cells so therapeutic benefits can be given early in this process.  
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Appendix 
 
Combined: Mean: Standard 
Deviation: 
Standard 
Error: 
P-value: 
Glaucoma Soma Size (µm) 14.62 2.35 0.33 0.49 
Control Soma Size (µm) 14.33 1.94 0.25 
Glaucoma Dendritic Length (µm) 1270.65 584.21 84.32 0.17 
Control Dendritic Length (µm) 1118.05 537.63 69.41 
Glaucoma Field Size (µm) 44584.51 30616.44 4419.10 0.56 
Control Field Size (µm) 41245.80 27502.98 3550.61 
Table 1. Shows the calculated results of the soma sizes, dendritic lengths, and field sizes across  
the glaucomatous and control retina. 
 
 
 
 
 
 
 
 
 
 
 
 
Ventral: Mean: Standard 
Deviation: 
Standard 
Error: 
P-value: 
Glaucoma Soma Size (µm) 15.75 2.23 0.31 0.02 
Control Soma Size (µm) 14.35 1.85 0.26 
Glaucoma Dendritic Length (µm) 1609.59 601.25 85.03 0.24 
Control Dendritic Length (µm) 1423.91 448.16 63.38 
Glaucoma Field Size (µm) 62061.35 36112.27 5107.05 0.48 
Control Field Size (µm) 55499.32 25904.13 3663.40 
Table 2. Shows the calculated results of the soma sizes, dendritic lengths, and field size of the ventral  
quadrant for the glaucomatous and control retina. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nasal: Mean: Standard 
Deviation: 
Standard 
Error: 
P-value: 
Glaucoma Soma Size (µm) 13.65 2.02 0.29 0.23 
Control Soma Size (µm) 14.31 2.07 0.29 
Glaucoma Dendritic Length (µm) 1007.04 417.06 58.98 0.09 
Control Dendritic Length (µm) 812.18 440.07 62.24 
Glaucoma Field Size (µm) 30991.42 15897.77 2248.28 0.42 
Control Field Size (µm) 26992.27 21155.37 2991.82 
Table 3. Shows the calculated results of the soma sizes, dendritic lengths, and field size of the nasal quadrant  
for the glaucomatous and control retina. 
